Skip to Navigation Skip to Content
  • Diagnostics
  • About Abbott
Abbott Menu Location
Alere is now Abbott
  • You are here
  • Location
  • iconAbout

    About

    Abbott is a world leader in rapid diagnostics at the point of care, with a focus on cardio metabolic disease, infectious disease and toxicology.

    Read More - About
    • Partnerships
    • Experience POCT Stories
    • Events
    • Abbott Locations
    • News Archive
    • Investors

      Investors

      Through our mission, we aim to improve clinical outcomes, reduce healthcare costs and deliver earnings growth to our investors.

      Read More - Investors Back -
    • Contacts (Africa)
    • Alere™ i Hospital Experience
  • iconViewpoints

    Viewpoints

    Point-of-care diagnostics is a growing and dynamic industry helping to improve clinical and economic outcomes globally. Discover a variety of expert viewpoints on new innovations, insights, and impacts that are shaping the future of diagnostics around the world.

    Read More - Viewpoints
    • What does the NHTSA data mean for the future of roadside testing?
    • Don't Take that Antibiotic. You Might Get. . .Fat?
    • Malaria - Plasmodium Knowlesi: The New Threat
    • What's the Value of Molecular Testing at the POC?
    • Considerations for Setting a THC Cut-Off to Detect Cannabis Use in Oral Fluid Screening
    • The Importance of Evidence-Based Medicine in Point-of-Care Testing
    • African First Ladies Mobilize to End Transmission of Mother-to-Child HIV and Syphilis
    • Allaying Employees' Concerns About Workplace Drug Testing
    • Antimicrobial Resistance: Getting Straight to the Point!
    • Overcoming the screening challenges of new psychoactive substances
    • Comprehensive Diabetes Patient Care Program Yields Measureable Results
    • Fighting the Growing Threat of Antimicrobial Resistance
    • Zika Virus: A Growing Public Health Threat
    • Progress in Total Analytical Error Reduction
    • Strengthening Referrals and Linkages in Swaziland
    • Designer Stimulant Testing: A Fast Moving Target
    • Left Behind in the Global Response to HIV
    • Eliminating Malaria in India
    • New Guidance for Physicians for Diagnosing C. diff
    • Clinicians Gather to Encourage Point-of-Care Testing in Latin America
    • Diagnostics at Davos: A Call to Deploy POCT to Address the Tolls of Antimicrobial Resistance
    • RSV. It's Not Just for Kids Anymore!
    • Improving Type 2 Diabetes and Hypertension Services in Honduras
    • The Global Threat of Drug-Resistant Tuberculosis - Are We Doing Enough?
    • Workplace Policies for Prescription Drugs
    • Diagnosis and Management of the Diabetes Epidemic in the Pacific Islands
    • Diagnostic Access in Africa: The Evolution of HIV Point-of-Care Testing in Uganda
    • The Benefits of Pre-Employment Drug Testing
    • The Expanded Role for Australian Community Pharmacy in Chronic Disease Management
    • Shifting Paradigms in Connectivity: How Knowledge Management Can Strengthen Point of Care Programs
    • "This Respiratory Season, FDA's Reclassification of Rapid Influenza Diagnostic Tests Can Contribute to Better Patient Outcomes"
    • Bringing "Health on Wheels" to At-Risk Teens in Cape Town
    • The Value of Random Drug Testing
    • Abbott and Alere have joined together bringing healthcare diagnostics to more people in more places around the world
  • iconProducts & Services

    Products & Services

    Abbott products give providers, physicians and patients access to the right information at the right time.

    Read More - Products & Services
    • Explore Product Lookup
    • Solutions
    • Cardiometabolic

      Cardiometabolic

      Our products and services include tests to assist in the diagnosis and management of many cardiometabolic factors and conditions.

      Read More - Cardiometabolic Back -
      • Coronary Heart Disease/ACS
      • Diabetes
      • Dyslipidemia
      • Heart Failure
      • Hyperglycemia
      • Oral Anticoagulation
      • Shortness of Breath
      • VTE
      • Patient Health Monitoring
    • Infectious Disease

      Infectious Disease

      Our products and services include tests to assist in the diagnosis and management of many infectious diseases.

      Read More - Infectious Disease Back -
      • C. difficile
      • Cryptosporidiosis
      • Dengue Fever
      • E. coli
      • Enterics
      • Epstein Barr Virus (EBV)
      • GI Parasites
      • Hepatitis
      • Hepatitis
      • Herpes Simplex Virus
      • HIV
      • Intestinal Inflammation
      • Legionnaire's Disease
      • Leptospira
      • Influenza (Flu)
      • Malaria
      • Mononucleosis
      • MRSA
      • Pneumonia
      • Ross River/Barmah Forest
      • RSV
      • Rubella
      • S. aureus
      • Strep A pharyngitis
      • Streptococcus pneumoniae
      • Syphilis
      • C-reactive Protein Diagnostic Tests
      • Tuberculosis
      • Other Infectious Disease
    • Toxicology

      Toxicology

      Broad drug and alcohol testing portfolio includes rapid analyzer-based tests, visual-read screening devices, laboratory tests, and immunoassay reagents.

      Read More - Toxicology Back -
      • Employers
      • Government
      • Hospitals
      • OEM
      • Medication Monitoring
      • Roadside Drug Testing
    • Toxicology Products & Services

      Toxicology Products & Services

      Alere™ Toxicology offers drug testing products and services that are used in a multitude of settings such as hospitals, clinics, physician offices, criminal justice, workplace, rehabilitation, occupational health clinics, and home testing.

      Read More - Toxicology Products & Services Back -
      • Laboratory Drug Screen
      • Oral Fluid Drug Test
      • Urine Drug Test
    • Other

      Other

      Our innovative diagnostics provide reliable and actionable information that enables informed decision-making by healthcare professionals at the point-of-care.

      Read More - Other Back -
      • Clinical Immunology
      • Oncology
      • POCT Data Management Platform
      • Women's Health
    • Browse by Brand

      Browse by Brand

      Our rapid diagnostic products are changing how healthcare is delivered-extending diagnosis and health management from the lab, doctor's office and hospital into people's homes.

      Read More - Browse by Brand Back -
      • Afinion
      • Alere Actim
      • BinaxNOW
      • Alere Cholestech LDX
      • Alere Determine
      • Alere hCG
      • Alere™ i
      • Alere NMP22
      • Alere PBP2a
      • Alere Pima CD4
      • Alere q
      • Alere TestPack
      • Alere Toxicology
      • AegisPOC
      • Clearview
      • Alere Determine
      • NHS Health Checks
      • i-STAT System
      • iCup
      • ID NOW™ (formerly Alere™ i )
      • NycoCard
      • RALS®
      • Standard Diagnostics
      • TECHLAB
      • Wampole
      • Additional Brands
    • NHS Health Checks
    • Patient Learning Series
    • For Patients
  • iconSupport

    Support

    Connect with us.

    Read More - Support
    • Contact Us
    • Product Document Search
    • Product Document Search
    • Product Demos
    • Terms of Trade
    • IQCP Support Resources

      IQCP Support Resources

      The Clinical Laboratory Improvement Amendments (CLIA) program recently introduced the Individualized Quality Control Plan (IQCP) as a new quality control option for nonwaived testing. We are pleased to provide you with materials to support your IQCPs.

      Read More - IQCP Support Resources Back -
    • Alere Instrument Warranty Registration
    • Laboratory Test Support Resources
    • HIPAA & Patient Information
    • Contacts (Africa)

      Contacts (Africa)

      Each territory in Africa is assigned to a specific Alere Business Manager who will have the responsibility to support you for all the essential commercial activities

      Read More - Contacts (Africa) Back -
      • Africa Business Development and Support Services
      • EABU - English East Africa
      • EWBU - English West Africa
      • NFBU & CABU
      • SABU - South Africa
      • ZABU - Southern Africa
  • iconCareers
  • iconContact Us
  • iconFrançais
  • iconPortuguês
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Linkedin
  • YouTube

Welcome.

Please select your country.

All Regions
  • Global
  • United States
  • Africa
  • Argentina
  • Australia
  • België / Belgique
  • Brasil
  • Canada
  • Česká republika
  • 中华人民共和国
  • Colombia
  • Denmark
  • Deutschland
  • España
  • France
  • India
  • Indonesia
  • Ireland
  • Italia
  • Japan
  • 대한민국
  • Malaysia
  • Nederland
  • New Zealand
  • Norge
  • Österreich
  • Portugal
  • Schweiz / Suisse
  • Suomi
  • Sverige
  • 臺灣
  • United Kingdom
  • Home
    • Viewpoints
    • What does the NHTSA data mean for the future of roadside testing?
    • Don't Take that Antibiotic. You Might Get. . .Fat?
    • Malaria - Plasmodium Knowlesi: The New Threat
    • What's the Value of Molecular Testing at the POC?
    • Considerations for Setting a THC Cut-Off to Detect Cannabis Use in Oral Fluid Screening
    • The Importance of Evidence-Based Medicine in Point-of-Care Testing
    • African First Ladies Mobilize to End Transmission of Mother-to-Child HIV and Syphilis
    • Allaying Employees' Concerns About Workplace Drug Testing
    • Antimicrobial Resistance: Getting Straight to the Point!
    • Overcoming the screening challenges of new psychoactive substances
    • Comprehensive Diabetes Patient Care Program Yields Measureable Results
    • Fighting the Growing Threat of Antimicrobial Resistance
    • Zika Virus: A Growing Public Health Threat
    • Progress in Total Analytical Error Reduction
    • Strengthening Referrals and Linkages in Swaziland
    • Designer Stimulant Testing: A Fast Moving Target
    • Left Behind in the Global Response to HIV
    • Eliminating Malaria in India
    • New Guidance for Physicians for Diagnosing C. diff
    • Clinicians Gather to Encourage Point-of-Care Testing in Latin America
    • Diagnostics at Davos: A Call to Deploy POCT to Address the Tolls of Antimicrobial Resistance
    • RSV. It's Not Just for Kids Anymore!
    • Improving Type 2 Diabetes and Hypertension Services in Honduras
    • The Global Threat of Drug-Resistant Tuberculosis - Are We Doing Enough?
    • Workplace Policies for Prescription Drugs
    • Diagnosis and Management of the Diabetes Epidemic in the Pacific Islands
    • Diagnostic Access in Africa: The Evolution of HIV Point-of-Care Testing in Uganda
    • The Benefits of Pre-Employment Drug Testing
    • The Expanded Role for Australian Community Pharmacy in Chronic Disease Management
    • Shifting Paradigms in Connectivity: How Knowledge Management Can Strengthen Point of Care Programs
    • "This Respiratory Season, FDA's Reclassification of Rapid Influenza Diagnostic Tests Can Contribute to Better Patient Outcomes"
    • Bringing "Health on Wheels" to At-Risk Teens in Cape Town
    • The Value of Random Drug Testing
    • Abbott and Alere have joined together bringing healthcare diagnostics to more people in more places around the world
  • Home
  • Viewpoints
Share
  • Facebook
  • Twitter
  • Google+
  • linkedIn
  • Pinterest
  • Email
Viewpoints

Viewpoints

impact 08/12/16

Comprehensive Diabetes Patient Care Program Yields Measureable Results

author
Gillian Parker
Senior Director, Diabetes, Cardiometabolic Business Unit
Comprehensive Diabetes Patient Care Program Yields Measureable Results

Healthcare professionals in traditional clinical practice have not often had the opportunity to validate best practices among a large sample of patients. Recently, however, the introduction of the Centers for Medicare and Medicaid (CMS) Medical Shared Savings Program (MSSP) for Accountable Care Organizations (ACOs), where providers are incented for reduced healthcare costs as well as improved quality of care, has brought with it the requirement for ACO participants to track and publicly report their results.

One such ACO in Texas covering thousands of patients with type 2 diabetes mellitus (T2DM) has implemented an innovative, multi-year, comprehensive care plan that includes point-of-care (POC) in-office testing for their patients. The results of this program, which were just presented at the 2016 American Diabetes Association annual meeting in New Orleans, demonstrated that the care plan significantly reduced healthcare costs while improving patients’ outcomes – effectively creating a blueprint that could be replicated on a much larger scale to help combat the growing epidemiological and economic impact of T2DM in the United States. 

The Rio Grande Valley (RGV) ACO in Southern Texas is one of more than 4,000 ACOs that were established as part of the Affordable Care Act’s Medicare Shared Savings Program to improve the quality of care and reduce unnecessary costs for Medicare Fee-For-Service beneficiaries. Despite what one could argue is a challenging demographic, the RGV ACO has realized significant savings while delivering quality scores that are among the best in the nation. The team at the RGV ACO has made diabetes control a focus and developed a set of innovative strategies to better manage this devastating condition that affects approximately 45% of their patient population – many of whom lack health literacy and are not educated about the role of a healthy diet and other lifestyle interventions that can help keep their T2DM stable. Additionally, many also do not have the money for their T2DM medication copayments, nor can they afford to go to the gym or buy nutrient-dense foods to support healthful lifestyles and eating patterns.

In addition to increased office efficiency, the benefits of POC testing for HbA1c and lipids include better delivery of care, education and training; prevention of additional visits for laboratory tests and follow-up; and additional patient compliance due to improved understanding.

RGV’s T2DM care program encompasses a wide range of strategies. Staff follow up patient visits with phone calls to remind them about blood glucose monitoring or to make medication adjustments, and uncontrolled patients are linked to nutritionists and certified diabetes educators. Staff are also alerted about care gaps through RGV’s electronic health records platform. RGV ACO uses point-of-care systems for measuring HbA1c and lipids because they allow clinicians to take immediate action on the test results. Getting HbA1c and lipid results during the visit means that they make the most of each visit with no need to spend additional time later to pull charts for review and follow up with patients after lab results are returned in the following days. Less time is spent chasing results and patients with phone calls and letters. In addition to increased office efficiency, the benefits of POC testing for HbA1c and lipids include better delivery of care, education, and training; prevention of additional visits for laboratory tests and follow-up; and additional patient compliance due to improved understanding. 

To date, more than 6,000 patients have been enrolled in this innovative care plan. Results have shown significant improvements in all quality measures, including HbA1c levels, blood pressure and tobacco non‐use, among others. From 2012 to 2014, the number of patients with comprehensive T2DM control increased from 12 to 49 percent, and the number of patients with HbA1c > 9 percent decreased from 17.81 to 12.83 percent. For the composite score of T2DM metrics, RGV achieved the top 1 percent of all ACOs in the nation. RGV ACO also reduced the per capita costs for its Medicare beneficiaries by 14 percent.

“The results of our program are especially gratifying because they show that T2DM can be successfully and cost-effectively managed among patients who are traditionally difficult – and expensive – to treat,” said Jose F. Pena, MD, Chief Executive Officer and Chief Medical Director, RGV ACO. “We now know definitively that there is no ‘silver bullet’ when it comes to managing T2DM. Healthcare providers need to use a wide range of interventions and strategies, including rapid point-of-care testing, frequent phone calls by care coordinators and others that are culturally tailored to their patients.”

While the RGV ACO is but one case study, it demonstrates that there can be a successful approach to comprehensive diabetes care in challenging populations that both reduces healthcare spending but also increases the quality of care. Improved control of diabetes and increased efficiencies in health care delivery are goals that bring with them benefits for diabetes patients of all ages and in private pay fee-for-service models as well.

  • Point of care testing
  • HbA1c
  • Improved patient outcomes
  • Healthcare costs
  • Diabetes
  • Blood glucose testing
  • Email
  • Facebook
  • Twitter
  • linkedIn
  • Google+
  • Print

Related Articles

  • View all
  • Hide all
  • This Respiratory Season, FDA’s Reclassification of Rapid Influenza Diagnostic Tests Can Contribute to Better Patient Outcomes

    insight

    This Respiratory Season, FDA’s Reclassification of Rapid Influenza Diagnostic Tests Can Contribute to Better Patient Outcomes

    View Now

    October 12, 2017

  • Shifting Paradigms in Connectivity: How Knowledge Management Can Strengthen Point of Care Programs

    insight

    Shifting Paradigms in Connectivity: How Knowledge Management Can Strengthen Point of Care Programs

    View Now

    July 19, 2017

  • The Expanded Role for Australian Community Pharmacy in Chronic Disease Management

    impact

    The Expanded Role for Australian Community Pharmacy in Chronic Disease Management

    View Now

    July 19, 2017

  • Diagnostic Access in Africa: The Evolution of HIV Point-of-Care Testing in Uganda

    impact

    Diagnostic Access in Africa: The Evolution of HIV Point-of-Care Testing in Uganda

    View Now

    May 31, 2017

  • Diagnosis and Management of the Diabetes Epidemic in the Pacific Islands

    insight

    Diagnosis and Management of the Diabetes Epidemic in the Pacific Islands

    View Now

    May 31, 2017

  • Improving Type 2 Diabetes and Hypertension Services in Honduras

    impact

    Improving Type 2 Diabetes and Hypertension Services in Honduras

    View Now

    March 20, 2017

  • Diagnostics at Davos: A Call to Deploy POCT to Address the Tolls of Antimicrobial Resistance

    insight

    Diagnostics at Davos: A Call to Deploy POCT to Address the Tolls of Antimicrobial Resistance

    View Now

    March 20, 2017

  • Clinicians Gather to Encourage Point-of-Care Testing in Latin America

    impact

    Clinicians Gather to Encourage Point-of-Care Testing in Latin America

    View Now

    January 23, 2017

  • New Guidance for Physicians for Accurately Diagnosing <em>C. difficile</em> Infection

    insight

    New Guidance for Physicians for Accurately Diagnosing C. difficile Infection

    View Now

    January 23, 2017

  • Left Behind in the Global Response to HIV

    insight

    Left Behind in the Global Response to HIV

    View Now

    November 14, 2016

  • Strengthening Referrals and Linkages in Swaziland

    impact

    Strengthening Referrals and Linkages in Swaziland

    View Now

    November 14, 2016

  • Reflecting on Progress in Total Analytical Error Reduction in Diagnostic Tests

    innovation

    Reflecting on Progress in Total Analytical Error Reduction in Diagnostic Tests

    View Now

    September 29, 2016

  • Fighting the Growing Threat of Antimicrobial Resistance

    impact

    Fighting the Growing Threat of Antimicrobial Resistance

    View Now

    September 29, 2016

  • Antimicrobial Resistance: Getting Straight to the Point! about Rapid CRP Testing in Primary Care

    impact

    Antimicrobial Resistance: Getting Straight to the Point! about Rapid CRP Testing in Primary Care

    View Now

    08/12/16

  • African First Ladies Mobilize to End Transmission of Mother-to-Child HIV and Syphilis

    impact

    African First Ladies Mobilize to End Transmission of Mother-to-Child HIV and Syphilis

    View Now

    06/30/16

  • The Importance of Evidence-Based Medicine in Point-of-Care Testing

    innovation

    The Importance of Evidence-Based Medicine in Point-of-Care Testing

    View Now

    6/30/2016

  • Molecular 101. What’s the Value of Molecular Testing at the POC?

    insight

    Molecular 101. What’s the Value of Molecular Testing at the POC?

    View Now

    06/30/16

 

Select a Topic

  • Insight
  • Innovation
  • Impact

Featured Articles:

  • Abbott and Alere have joined together bringing healthcare diagnostics to more people in more places around the world
  • The Value of Random Drug Testing
  • Bringing “Health on Wheels” to At-risk Teens in Cape Town
  • This Respiratory Season, FDA’s Reclassification of Rapid Influenza Diagnostic Tests Can Contribute to Better Patient Outcomes
  • Shifting Paradigms in Connectivity: How Knowledge Management Can Strengthen Point of Care Programs
  • The Expanded Role for Australian Community Pharmacy in Chronic Disease Management

Sign Up for Email Updates




Please enter valid email address.

Please enter correct answer.

Thank you for signing up.

Stay informed

Sign up to receive valuable updates from Abbott.

Click here to sign up
  • About
    • Partnerships
    • Experience POCT Stories
    • Events
    • Abbott Locations
    • Contacts (Africa)
    • Alere™ i Hospital Experience
  • Viewpoints
  • Products & Services
    • Solutions
    • Cardiometabolic
    • Infectious Disease
    • Toxicology
    • Toxicology Products & Services
    • Other
    • Browse by Brand
    • NHS Health Checks
    • Patient Learning Series
    • For Patients
  • Support
    • Contact Us
    • Product Document Search
    • Product Document Search
    • Product Demos
    • Terms of Trade
    • IQCP Support Resources
    • Alere Instrument Warranty Registration
    • Laboratory Test Support Resources
    • HIPAA & Patient Information
    • Contacts (Africa)
  • Careers

Explore more with Abbott

  • About Abbott
  • Abbott Diagnostics
  • TestTargetTreat.com
  • AlereToxicology.com
  • PTINR.com
  • AlereToxicology.co.uk
  • AlereHealthcareConnections.com
  • eScreen.com
  • AlereCoag.com

©2019 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage. Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. GDPR Statement (last updated: May 2018) | California Transparency in Supply Chains Act | Declaration for California Compliance Law.

Not all products are available in all regions. Check with your local representative for availability in specific markets. For In Vitro Diagnostic Use Only. See CTI Sheets on pointofcare.abbott for complete product information.

Abbott - A Leader in Rapid Point-of-Care Diagnostics.

Based on your current location, the content on this page may not be relevant for your country.
Please click here to return to the homepage. Alternatively, click the X button to acknowledge and proceed.
Close

contact us
More
Info?